These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38150770)

  • 1. Eyedrop delivery of therapeutic proteins with zwitterionic polymers to treat dry age-related macular degeneration.
    Jiang Y; Fu X; Shao M; Chang W; Zhang H; Liu Z
    Biomaterials; 2024 Mar; 305():122429. PubMed ID: 38150770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultra-small-size Astragaloside-IV loaded lipid nanocapsules eye drops for the effective management of dry age-related macular degeneration.
    Sun R; Zhang A; Ge Y; Gou J; Yin T; He H; Wang Y; Zhang G; Kong J; Shang L; Tao X; Zhang Y; Tang X
    Expert Opin Drug Deliv; 2020 Sep; 17(9):1305-1320. PubMed ID: 32538226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment.
    Shen J; Gao H; Chen L; Jiang Y; Li S; Chao Y; Liu N; Wang Y; Wei T; Liu Y; Li J; Chen M; Zhu J; Liang J; Zhou X; Zhang X; Gu P; Chen Q; Liu Z
    Sci Adv; 2023 Jan; 9(4):eabq3104. PubMed ID: 36706184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000-patient population.
    Babizhayev MA; Burke L; Micans P; Richer SP
    Clin Interv Aging; 2009; 4():31-50. PubMed ID: 19503764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye.
    Bisht R; Jaiswal JK; Rupenthal ID
    Med Hypotheses; 2017 Jun; 103():5-9. PubMed ID: 28571808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
    Myles ME; Neumann DM; Hill JM
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases.
    Babizhayev MA; Kasus-Jacobi A
    Curr Clin Pharmacol; 2009 Jan; 4(1):4-37. PubMed ID: 19149498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraocular sustained drug delivery using implantable polymeric devices.
    Yasukawa T; Ogura Y; Sakurai E; Tabata Y; Kimura H
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2033-46. PubMed ID: 16263193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in Formulation Approaches for Sustained Drug Delivery to the Posterior Segment of the Eye.
    Biswas A; Choudhury AD; Bisen AC; Agrawal S; Sanap SN; Verma SK; Mishra A; Kumar S; Bhatta RS
    AAPS PharmSciTech; 2023 Oct; 24(8):217. PubMed ID: 37891392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-aqueous formulations in topical ocular drug delivery - A paradigm shift?
    Agarwal P; Rupenthal ID
    Adv Drug Deliv Rev; 2023 Jul; 198():114867. PubMed ID: 37178927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal hydrogels for sustained release of therapeutic proteins.
    Ilochonwu BC; Urtti A; Hennink WE; Vermonden T
    J Control Release; 2020 Oct; 326():419-441. PubMed ID: 32717302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New ophthalmic drug delivery systems.
    Castro-Balado A; Mondelo-García C; Zarra-Ferro I; Fernández-Ferreiro A
    Farm Hosp; 2020 Jul; 44(4):149-157. PubMed ID: 32646346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanotherapies for the Treatment of Age-Related Macular Degeneration (AMD) Disease: Recent Advancements and Challenges.
    Rapalli VK; Gorantla S; Waghule T; Mahmood A; Singh PP; Dubey SK; Saha RN; Singhvi G
    Recent Pat Drug Deliv Formul; 2019; 13(4):283-290. PubMed ID: 31951173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Low Concentration of Tacrolimus/Semifluorinated Alkane (SFA) Eyedrop Suppresses Intraocular Inflammation in Experimental Models of Uveitis.
    De Majumdar S; Subinya M; Korward J; Pettigrew A; Scherer D; Xu H
    Curr Mol Med; 2017; 17(3):211-220. PubMed ID: 28782485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ophthalmic Drops with Nanoparticles Derived from a Natural Product for Treating Age-Related Macular Degeneration.
    Xin G; Zhang M; Zhong Z; Tang L; Feng Y; Wei Z; Li S; Li Y; Zhang J; Zhang B; Zhang M; Rowell N; Chen Z; Niu H; Yu K; Huang W
    ACS Appl Mater Interfaces; 2020 Dec; 12(52):57710-57720. PubMed ID: 33320520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein conjugates and fusion proteins as ocular therapeutics.
    Mehta SC; Kelley RF; Tesar DB
    Drug Discov Today; 2019 Aug; 24(8):1440-1445. PubMed ID: 31202674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydrogel eye drops as a non-invasive drug carrier for topical enhanced Adalimumab permeation and highly efficient uveitis treatment.
    Chen Z; Yang M; Wang Q; Bai J; McAlinden C; Skiadaresi E; Zhang J; Pan L; Mei C; Zeng Z; Yu J; Feng Y; Jiang Z; Xu W; Xu H; Ye X; He H; Wang Q; Deng J; Huang J
    Carbohydr Polym; 2021 Feb; 253():117216. PubMed ID: 33278980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chitosan-Polycaprolactone Core-Shell Microparticles for Sustained Delivery of Bevacizumab.
    Jiang P; Jacobs KM; Ohr MP; Swindle-Reilly KE
    Mol Pharm; 2020 Jul; 17(7):2570-2584. PubMed ID: 32484677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-acetylcarnosine lubricant eyedrops possess all-in-one universal antioxidant protective effects of L-carnosine in aqueous and lipid membrane environments, aldehyde scavenging, and transglycation activities inherent to cataracts: a clinical study of the new vision-saving drug N-acetylcarnosine eyedrop therapy in a database population of over 50,500 patients.
    Babizhayev MA; Micans P; Guiotto A; Kasus-Jacobi A
    Am J Ther; 2009; 16(6):517-33. PubMed ID: 19487926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review on recent drug delivery systems for posterior segment of eye.
    Nayak K; Misra M
    Biomed Pharmacother; 2018 Nov; 107():1564-1582. PubMed ID: 30257375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.